Capital Advisors Inc. OK Has $41.67 Million Holdings in Pfizer Inc. (NYSE:PFE)

Capital Advisors Inc. OK grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 3.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,439,745 shares of the biopharmaceutical company’s stock after acquiring an additional 48,314 shares during the quarter. Capital Advisors Inc. OK’s holdings in Pfizer were worth $41,666,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. bought a new stake in Pfizer during the 1st quarter worth $315,000. Norden Group LLC raised its holdings in Pfizer by 26.8% in the 1st quarter. Norden Group LLC now owns 30,336 shares of the biopharmaceutical company’s stock valued at $842,000 after buying an additional 6,404 shares during the last quarter. Connecticut Wealth Management LLC boosted its position in Pfizer by 11.8% during the 1st quarter. Connecticut Wealth Management LLC now owns 18,279 shares of the biopharmaceutical company’s stock worth $507,000 after buying an additional 1,936 shares during the period. Sippican Capital Advisors grew its holdings in Pfizer by 21.5% during the 1st quarter. Sippican Capital Advisors now owns 82,762 shares of the biopharmaceutical company’s stock worth $2,297,000 after acquiring an additional 14,618 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. raised its stake in shares of Pfizer by 6.0% during the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 137,125 shares of the biopharmaceutical company’s stock valued at $3,805,000 after acquiring an additional 7,718 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of the stock in a transaction on Wednesday, October 30th. The shares were acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at $282,400. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on PFE. UBS Group raised their price objective on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Citigroup began coverage on shares of Pfizer in a report on Friday, October 25th. They issued a “neutral” rating and a $30.00 target price on the stock. Wells Fargo & Company increased their price target on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Barclays boosted their price target on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Finally, StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Eight investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Pfizer has an average rating of “Moderate Buy” and a consensus price target of $33.58.

Pfizer Stock Down 0.8 %

PFE opened at $28.08 on Friday. The company’s 50-day moving average price is $29.03 and its two-hundred day moving average price is $28.57. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $31.54. The stock has a market cap of $159.12 billion, a price-to-earnings ratio of 37.95, a PEG ratio of 0.90 and a beta of 0.67.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.40% and a net margin of 7.07%. The business had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. During the same quarter in the prior year, the business earned ($0.17) earnings per share. Pfizer’s revenue for the quarter was up 31.2% on a year-over-year basis. As a group, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 5.98%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio is currently 227.03%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.